4 Papers
Lu Miao is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Androgen receptor & Biology. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
Siu Chiu Chan,Luke A. Selth,Yingming Li,Michael D. Nyquist,Lu Miao,James E. Bradner,Ganesh V. Raj,Wayne D. Tilley,Scott M. Dehm +8 more
TL;DR: This study demonstrates that AR-Vs broadly restore AR chromatin binding events that are otherwise suppressed during endocrine therapy, and provides pre-clinical rationale for BET inhibition as a strategy for inhibiting expression and Chromatin binding of AR-V in PCa.
Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation.
TL;DR: The data suggest that therapeutic strategies aimed at preventing AR nuclear translocation and genomic AR signaling alone may not completely abrogate AR signaling, and elucidation of mechanisms that underlie non-genomic AR signaling may identify potential mechanisms of resistance to current anti-androgens and help developing novel therapies that abolish all AR signaling in prostate cancer.
Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer.
Lu Miao,Lin Yang,Lin Yang,Rui Li,Daniel Nava Rodrigues,Mateus Crespo,Jer Tsong Hsieh,Wayne D. Tilley,Johann S. de Bono,Luke A. Selth,Ganesh V. Raj +10 more
TL;DR: Findings demonstrate that de-repression of Snail and induction of EMP is an adaptive response to enzalutamide with implications for therapy resistance and elucidate a mechanism explaining the inverse relationship between AR and Snail.
The social network of PELP1 and its implications in breast and prostate cancers.
Vijay K. Gonugunta,Lu Miao,Gangadhara R. Sareddy,Preethi Ravindranathan,Ratna K. Vadlamudi,Ganesh V. Raj +5 more
TL;DR: The expression and localization of PELP1 are dysregulated in hormonal cancers including breast and prostate cancers and this review focuses on the interactive functions and therapeutic and prognostic significance of P ELP1 in breast and cancer.